Qingdao Chia Tai Haier Pharmaceutical

Qingdao Chia Tai Haier Pharmaceutical is a joint venture between the CP Pharmaceutical Group (Sino Biopharmaceutical) and the Haier Group, established in 1994. The company is a key player in the Chinese pharmaceutical market, focusing on the development and production of treatments for bone metabolism, cardiovascular diseases, and endocrine disorders. Its flagship products include Alfacalcidol soft capsules and various calcium-based supplements, which have established the company as a leader in the bone health segment. With a strong emphasis on GMP-compliant manufacturing and R&D, the company operates extensive facilities in Qingdao to support its diverse product portfolio. It continues to expand its reach through strategic partnerships and a robust distribution network across China.